CXCR4-blocking agents, such as the neutralizing antibody MDX1338 or Ulocuplumab, were reported to efficiently reduce migration and invasion of osteosarcoma, alveolar rhabdomyosarcoma and myeloma cells and suppress the CXCR4-driven Epithelial-to-mesenchymal (EMT)-like phenotype (45–47), supporting the specific targeting of CXCR4 in therapy. The gene discussed is CXCR4; the disease is plasma cell myeloma.